SCYNEXIS, Inc. (SCYX)
3.785
-0.02
(-0.66%)
USD |
NASDAQ |
Oct 23, 16:00
3.77
-0.02
(-0.40%)
After-Hours: 20:00
SCYNEXIS EPS Diluted (Quarterly) : 0.6256 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.6256 |
| March 31, 2026 | -3.344 |
| December 31, 2025 | 2.252 |
| September 30, 2025 | -1.377 |
| June 30, 2025 | -1.107 |
| March 31, 2025 | -0.8724 |
| December 31, 2024 | -0.9339 |
| September 30, 2024 | -0.0578 |
| June 30, 2024 | -0.298 |
| March 31, 2024 | 0.0085 |
| December 31, 2023 | -0.565 |
| September 30, 2023 | -0.0367 |
| June 30, 2023 | 2.458 |
| March 31, 2023 | -0.7093 |
| December 31, 2022 | -0.4415 |
| September 30, 2022 | -0.6228 |
| June 30, 2022 | -0.3083 |
| March 31, 2022 | -0.1818 |
| December 31, 2021 | -1.049 |
| September 30, 2021 | -0.0574 |
| June 30, 2021 | -0.2173 |
| March 31, 2021 | -0.2262 |
| December 31, 2020 | -3.916 |
| September 30, 2020 | -0.2793 |
| June 30, 2020 | -6.375 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7186 |
| December 31, 2019 | -2.141 |
| September 30, 2019 | -1.184 |
| June 30, 2019 | -1.577 |
| March 31, 2019 | -4.645 |
| December 31, 2018 | 0.4048 |
| September 30, 2018 | 0.0746 |
| June 30, 2018 | -2.30 |
| March 31, 2018 | -1.192 |
| December 31, 2017 | -2.620 |
| September 30, 2017 | -3.10 |
| June 30, 2017 | -1.60 |
| March 31, 2017 | -2.50 |
| December 31, 2016 | -1.402 |
| September 30, 2016 | -4.80 |
| June 30, 2016 | -5.60 |
| March 31, 2016 | -5.20 |
| December 31, 2015 | -6.032 |
| September 30, 2015 | -6.115 |
| June 30, 2015 | -7.80 |
| March 31, 2015 | -7.50 |
| December 31, 2014 | -3.612 |
| September 30, 2014 | -4.50 |
| June 30, 2014 | -9.80 |
| March 31, 2014 | -65.70 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 7.397M |
| Revenue (Quarterly) | 0.235M |
| Total Expenses (Quarterly) | -7.162M |
| Enterprise Value | -14.56M |
| Earnings Yield | -48.70% |
| Normalized Earnings Yield | -58.18 |